The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.226%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 31.50
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

4 Aug 2022 07:00

RNS Number : 8533U
Duke Royalty Limited
04 August 2022
 

4 August 2022

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and North America, is pleased to provide the following trading update for its first financial quarter ended 30 June 2022 ("Q1 FY23"), and to provide guidance on trading for the second quarter of the Company's 2023 financial year, ending 30 September 2022 ("Q2 FY23").

Financial Highlights:

· Normalised cash revenue* for Q1 FY23 reached a new record of £5.1 million, an increase of 9% on the previous quarter and an 78% increase over Q1 FY22, exceeding the Company's expectations of £5.0 million

· Q1 FY23 total cash revenue** also totalled £5.1 million, reflecting the fact that no buyouts or equity sales occurred during the quarter

 

Normalised Cash Revenue*

Total Cash Revenue**

Q1 FY22

£2.9 million

£2.9 million

Q2 FY22

£3.3 million

£4.9 million

Q3 FY22

£3.9 million

£3.9 million

Q4 FY22

£4.7 million

£6.7 million

Q1 FY23

£5.1 million

£5.1 million

 

* Normalised cash revenue excludes redemption premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's royalty partners plus cash gains received from the sales of equity assets and redemption premiums

 

· Based on current trading, Duke expects Q2 FY23 normalised cash revenue to increase to £5.2 million

Operational Highlights:

· Completed a £2.3m follow-on investment into specialist residential and domiciliary care provider Tristone Healthcare Limited to fund the acquisition of Beyond Limits (Plymouth) Limited, a profitable operator of specialist care homes predominantly in the Southwest of England. The financing increases Duke's total investment into Tristone to £14.4 million.

· Completed a £3.1m follow-on investment into the IT managed services provider, InTec Business Solutions Limited to fund the acquisition of Astec Computing (UK), a profitable I.T. managed services business with a 30 year trading history. The financing increases Duke's total investment into InTec to £17.1 million.

· £20m equity fundraising completed in May 2022. The proceeds of the equity raise enable the temporary pay down of existing debt, reducing interest costs and cash drag, in turn increasing total liquidity available to the Company for additional investments into existing Royalty Partners deploying a buy and build acquisition strategy, and new opportunities.

· Paid a dividend of 0.70p per share paid for the quarter, representing an annualised yield of over 8% at the current share price with the dividend well covered by operating cashflow.

Neil Johnson, CEO of Duke Royalty, said:

"Despite the headwinds prevalent in the world economy and the volatility seen in global stock markets, it was business as usual for Duke in the quarter. I am pleased to report that the Company produced another record of normalised cash revenue in Q1 FY23 and I expect this growth trend to continue into Q2 FY23 by virtue of Duke's annual yield adjustments linked to underlying companies' revenue performance in this inflationary macro-environment. Duke's secured position and exposure to 48 different underlying operating companies provides investors with exposure to a diverse portfolio of profitable, long-established businesses in low-risk sectors which are well managed to navigate through challenging environments.

The Company's flexible model continues to be attractive to SMEs operating 'buy and build' acquisition strategies and management buy-out opportunities, as such we continue to review a healthy number of new investment opportunities. While we have increased total liquidity available, we will continue to deploy capital prudently through our rigorous due diligence and evaluation process in light of the changing macro-economic conditions. We look forward to updating our shareholders on our progress in the near future."

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

 

Duke Royalty Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 730 613

Cenkos Securities plc 

(Nominated Adviser

and Joint Broker)

 

Stephen Keys / Callum Davidson / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell / Richard Bicknell / Max Richardson

+44 (0) 20 3757 6882 dukeroyalty@secnewgate.co.uk

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFLITIIVIIF
Date   Source Headline
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.